Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 961 to 970 of 1535 total matches.

Drugs for Helicobacter pylori Infection

   
The Medical Letter on Drugs and Therapeutics • Jul 17, 2017  (Issue 1525)
information call: 800-211-2769 114 The Medical Letter ® Vol. 59 (1525) July 17, 2017 higher with bismuth ...
About 50% of the world’s population is infected with Helicobacter pylori. These gastric bacteria can cause chronic inflammation and have been associated with development of gastritis, peptic ulcer disease, gastric adenocarcinoma, and gastric mucosa-associated lymphoid tissue (MALT) lymphoma. Eradication of H. pylori can promote gastric healing, prevent recurrence of duodenal and gastric ulcers, and reduce the incidence of gastric cancer. Guidelines for treatment of H. pylori infection were updated recently.
Med Lett Drugs Ther. 2017 Jul 17;59(1525):113-7 |  Show IntroductionHide Introduction

Management of Opioid Withdrawal Symptoms

   
The Medical Letter on Drugs and Therapeutics • Aug 27, 2018  (Issue 1554)
. For further information call: 800-211-2769 138 The Medical Letter ® Vol. 60 (1554) August 27, 2018 Table 1 ...
Pharmacologic management of opioid withdrawal symptoms can reduce the intensity of drug craving and improve treatment retention in patients with opioid use disorder who will receive maintenance treatment. Withdrawal management without subsequent maintenance treatment is associated with high rates of relapse, overdose death, and HIV and/or hepatitis C virus infection. Several guidelines on management of opioid withdrawal are available. Maintenance treatment of opioid use disorder was reviewed in a previous issue.
Med Lett Drugs Ther. 2018 Aug 27;60(1554):137-42 |  Show IntroductionHide Introduction

Esketamine Nasal Spray (Spravato) for Treatment-Resistant Depression

   
The Medical Letter on Drugs and Therapeutics • Apr 08, 2019  (Issue 1569)
The Medical Letter ® Vol. 61 (1569) April 8, 2019 taking the same regimen or switch to an intranasal placebo ...
The FDA has approved esketamine (Spravato – Janssen), an N-methyl-D-aspartate (NMDA) receptor antagonist, for intranasal treatment (in conjunction with an oral antidepressant) of adults with treatment-resistant depression (TRD). This is the first FDA approval for esketamine, which is the S-enantiomer of the intravenous anesthetic ketamine (Ketalar, and generics). In recent years, IV ketamine has been increasingly used (off-label) for treatment of TRD.
Med Lett Drugs Ther. 2019 Apr 8;61(1569):54-6 |  Show IntroductionHide Introduction

Lasmiditan (Reyvow) and Ubrogepant (Ubrelvy) for Acute Treatment of Migraine

   
The Medical Letter on Drugs and Therapeutics • Mar 09, 2020  (Issue 1593)
hours 5-7 hours 36 The Medical Letter ® Vol. 62 (1593) March 9, 2020 to mild or none) at 2 hours ...
Lasmiditan (Reyvow – Lilly), an oral serotonin (5-HT1F) receptor agonist, and ubrogepant (Ubrelvy – Allergan), an oral calcitonin gene-related peptide (CGRP) receptor antagonist, have been approved by the FDA for acute treatment of migraine with or without aura in adults.
Med Lett Drugs Ther. 2020 Mar 9;62(1593):35-9 |  Show IntroductionHide Introduction

Fremanezumab (Ajovy) and Galcanezumab (Emgality) for Migraine Prevention

   
The Medical Letter on Drugs and Therapeutics • Nov 05, 2018  (Issue 1559)
were excluded, as were those with a history 178 The Medical Letter ® Vol. 60 (1559) November 5, 2018 ...
The FDA has approved two subcutaneously injected calcitonin gene-related peptide (CGRP) antagonists, fremanezumab-vfrm (Ajovy – Teva) and galcanezumab-gnlm (Emgality – Lilly), for migraine prevention in adults. Fremanezumab and galcanezumab are the second and third subcutaneously injected monoclonal antibodies that target the CGRP pathway to be approved by the FDA for this indication; erenumab-aooe (Aimovig), which targets the CGRP receptor, was the first.
Med Lett Drugs Ther. 2018 Nov 5;60(1559):177-80 |  Show IntroductionHide Introduction

Istradefylline (Nourianz) for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • Feb 10, 2020  (Issue 1591)
. 21 The Medical Letter ® Vol. 62 (1591) February 10, 2020 Table 3. Some Drugs for Parkinson’s ...
The FDA has approved istradefylline (Nourianz — Kyowa Kirin), an oral adenosine A2A receptor antagonist, for use as an adjunct to carbidopa/levodopa in adults with Parkinson's disease (PD) who experience "off" episodes. Istradefylline is the first adenosine A2A receptor antagonist to be approved in the US; it has been available in Japan since 2013.
Med Lett Drugs Ther. 2020 Feb 10;62(1591):20-3 |  Show IntroductionHide Introduction

Two Vonoprazan Combinations (Voquezna) for H. pylori

   
The Medical Letter on Drugs and Therapeutics • Oct 31, 2022  (Issue 1662)
copackaged with amoxicillin and with both amoxicillin and clarithromycin. The Medical Letter ® Vol. 64 ...
The FDA has approved vonoprazan, a potassium-competitive acid blocker, copackaged with amoxicillin (Voquezna Dual Pak – Phathom) and with amoxicillin and clarithromycin (Voquezna Triple Pak) for treatment of Helicobacter pylori infection in adults. Vonoprazan is the first potassium-competitive acid blocker to be approved in the US. It has been available in Japan for treatment of various acid-related disorders since 2014. Vonoprazan is not available alone in the US.
Med Lett Drugs Ther. 2022 Oct 31;64(1662):169-72 |  Show IntroductionHide Introduction

Immunization of College Students Against Meningococcal Disease

   
The Medical Letter on Drugs and Therapeutics • Aug 07, 2000  (Issue 1084)
Street, New Rochelle, N.Y. 10801 • A Nonprofit Publication Vol. 42 (W1084A) August 7, 2000 REPRODUCED ...
The US Public Health Service Advisory Committee on Immunization Practices has recently published new recommendations for prevention and control of meningococcal disease in college students.
Med Lett Drugs Ther. 2000 Aug 7;42(1084):69 |  Show IntroductionHide Introduction

Ceritinib (Zykadia) for Non-Small Cell Lung Cancer

   
The Medical Letter on Drugs and Therapeutics • Jul 21, 2014  (Issue 1447)
of ceritinib on progression-free and overall survival remains to be determined. 63 The Medical Letter ® Vol ...
Ceritinib (Zykadia – Novartis), an oral tyrosine kinase inhibitor, has received accelerated approval from the FDA for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib (Xalkori). It is the second tyrosine kinase inhibitor to be approved for ALK-positive metastatic NSCLC; crizotinib was the first. Translocations of the ALK gene are found in about 5% of lung cancers; they occur predominantly in nonsmokers with adenocarcinoma.
Med Lett Drugs Ther. 2014 Jul 21;56(1447):62-3 |  Show IntroductionHide Introduction

A Transcutaneous Electrical Nerve Stimulation Device (Cefaly) for Migraine Prevention

   
The Medical Letter on Drugs and Therapeutics • Aug 18, 2014  (Issue 1449)
. 74 The Medical Letter ® Vol. 56 (1449) August 18, 2014 1. Approximate cost according ...
The FDA has approved the use of a transcutaneous electrical nerve stimulation device (Cefaly – Cefaly Technology) for prevention of episodic migraine in patients ≥18 years old. The first device to be approved in the US for migraine prevention, it is available in Canada and Europe for treatment and prevention of migraines. A transcranial magnetic stimulation device (SpringTMS - eNeura Therapeutics) recently approved by the FDA for treatment of migraine preceded by aura will be reviewed in a future issue.
Med Lett Drugs Ther. 2014 Aug 18;56(1449):78 |  Show IntroductionHide Introduction